Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Carbamazepine intervention in a patient with efavirenz-induced liver injury.

Jacobs TG, Burger DM, Pranger AD, Khoo SH, Drenth JPH, van Crevel R.

AIDS. 2019 May 1;33(6):1097-1098. doi: 10.1097/QAD.0000000000002116. No abstract available.

PMID:
30946165
2.

The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.

Pranger AD, van der Werf TS, Kosterink JGW, Alffenaar JWC.

Drugs. 2019 Feb;79(2):161-171. doi: 10.1007/s40265-018-1043-y. Review.

3.

[Fatal intoxication with nicotine for e-cigarette].

van der Meer DH, Pranger AD, Jansen I, Wilms EB, Kieft H, Maring JG.

Ned Tijdschr Geneeskd. 2017;161:D1591. Dutch.

PMID:
28984212
4.

Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis.

Alsaad N, van Altena R, Pranger AD, van Soolingen D, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW.

Eur Respir J. 2013 Aug;42(2):504-12. doi: 10.1183/09031936.00114812. Epub 2012 Oct 25.

5.

Linezolid: safety and efficacy monitoring.

Bolhuis MS, Pranger AD, Alffenaar JW.

Eur Respir J. 2012 May;39(5):1275-6; author reply 1276-7. doi: 10.1183/09031936.00200911. No abstract available.

6.

Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams.

Bolhuis MS, Panday PN, Pranger AD, Kosterink JG, Alffenaar JC.

Pharmaceutics. 2011 Nov 18;3(4):865-913. Review.

7.

Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.

Pranger AD, Alffenaar JW, Aarnoutse RE.

Curr Pharm Des. 2011;17(27):2900-30. Review.

PMID:
21834759
8.

Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis.

Pranger AD, Kosterink JG, van Altena R, Aarnoutse RE, van der Werf TS, Uges DR, Alffenaar JW.

Ther Drug Monit. 2011 Jun;33(3):350-4. doi: 10.1097/FTD.0b013e31821b793c.

PMID:
21544017
9.

Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience.

Pranger AD, van Altena R, Aarnoutse RE, van Soolingen D, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2011 Oct;38(4):888-94. doi: 10.1183/09031936.00176610. Epub 2011 Feb 10.

10.

Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Bolhuis MS, Panday PN, Pranger AD, Kosterink JG, Alffenaar JW.

Pharmaceutics. 2011 Nov 18;3(4):865-913. doi: 10.3390/pharmaceutics3040865.

11.

Supplemental Content

Loading ...
Support Center